• $3.5M
    Market Cap
  • -77.07%
    1-Year Change
  • Specialty Chemicals
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: 16
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

RYET to Enter Malaysian Healthcare Through Exclusive Cogni AI License to BioNexus Gene Lab

Ruanyun Edai Technology Inc. (NASDAQ: RYET) has signed a definitive agreement to grant BioNexus Gene Lab Corp. (NASDAQ: BGLC) an exclusive 10-20 year license for its Cogni AI document-intelligence platform in Malaysian healthcare. RYET will receive 560,000 BGLC shares and a 10% royalty on qualifying technology receipts. The deal aligns with Malaysia's RM1 billion healthcare digitalization initiative, though neither company has secured government contracts yet.

10/05/2026, 9:00 AM • GlobeNewswire

BioNexus Gene Lab Corp Signs Strategic Partnership Term Sheet with BirchBioMed Inc.

BioNexus Gene Lab Corp entered a strategic partnership with BirchBioMed Inc. to invest $10 million and collaborate on advancing FS2 topical platform in Southeast Asia, focusing on dermal regeneration and fibrosis control.

10/20/2025, 8:00 AM • GlobeNewswire

Peers

Statistics

More
Day Range
$1.19
$1.19
$1.19
1-Year Range
$1.19
$5.48
$1.19
Latest Close$1.19
Change
$0.00 (0.00%)
Volume1,136
Market Cap$3.5M
Shares Outstanding2.9M
P/E (TTM)-1.02
Diluted EPS (TTM)-$1.16
Enterprise Value$2.3M

Information as of 10/22/2026

Company Profile

BIONEXUS GENE LAB CORP
https://www.bionexusgenelab.com
$3.5M
Market Cap
-$2.6M
Net Income
Sector: Basic Materials
Industry: Specialty Chemicals
Menara UOA Bangsar, Kuala Lumpur, Malaysia, 59000
60 1 307 241 6898

BioNexus Gene Lab Corp., together with its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding. It offers various chemical raw material products, including polyester resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; polyester resin 9509, a general-purpose material used in the production of marine boats and water slides; and polyester resin 2802, which is used as a component in the pultrusion process. The company's products are used in producing various finished goods, such as handrails, bench tops, and automotive and aero parts; paneling for hospital, laboratory, and industrial clean rooms; and covers for various instruments used in manufacturing. It develops and provides non-invasive liquid biopsy tests for the early detection of biomarkers. BioNexus Gene Lab Corp. was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

Key Executives

  • Su-Leng Tan
  • Set Fui Chong
  • Kwan Wah Chan
  • Too Kam Tham

Current Ownership Distribution

  • Insiders18.2M (98.61%)
  • Mutual Funds241,615 (1.31%)
  • Institutions14,617 (0.08%)
  • Other0 (0.00%)